Anna Butusova

Anna Butusova

Auto-generated profile, based on publicly available information

Anna Butusova

BostonGene Corporation, Waltham, Massachusetts

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2023 in Problems of Virology
Verified
Journal Article
Open access
PDF file
YIYury Ivin
Yury Ivin
ABAnna A. Butusova
Anna A. Butusova
EGEkaterina Gladneva
Ekaterina Gladneva
GKGalina Ya. Kolomijtseva
Galina Ya. Kolomijtseva
YKYusuf K. Khapchaev
Yusuf K. Khapchaev
ИАИшмухаметов Айдар Айратович
Ишмухаметов Айдар Айратович
Introduction. Infection of cells with encephalomyocarditis virus type 1 (EMCV-1, Cardiovirus A: Picornaviridae) is accompanied by suppression of cellular protein synthesis. The main role in the inhibition of cellular translation is assigned to the L and 2A «security» proteins. The mechanism of the possible influence of the L protein on cellular translation is unknown. There are hypotheses about the mechanism of influence of 2A protein on the efficiency of cap-dependent translation, which are based on interaction with translation factors and ribosome subunits. However, the available experimental data are contradictory, obtained using different approaches, and do not form a unified model of the interaction between the L and 2A proteins and the cellular translation machinery. Aim. To study the role of L and 2A «security» proteins in the suppression of translation of cellular proteins and the efficiency of translation and processing of viral proteins in infected cells. Materials and methods. Mutant variants of EMCV-1 were obtained to study the properties of L and 2A viral proteins: Zfmut, which has a defective L; Δ2A encoding a partially deleted 2A; ZfmutΔ2A containing mutations in both proteins. Translational processes in infected cells were studied by Western-blot and the pulse method of incorporating radioactively labeled amino acids (14C) into newly synthesized proteins, followed by radioautography. Results. The functional inactivation of the 2A protein does not affect the inhibition of cellular protein synthesis. A direct correlation was found between the presence of active L protein and specific inactivation of cellular protein synthesis at an early stage of viral infection. Nonspecific suppression of the translational processes of the infected cell, accompanied by phosphorylation of eIF2α, occurs at the late stage of infection. Partial removal of the 2A protein from the EMCV-1 genome does not affect the development of this process, while inactivation of the L protein accelerates the onset of complete inhibition of protein synthesis. Partial deletion of the 2A disrupts the processing of viral capsid proteins. Suppression of L protein functions leads to a decrease in the efficiency of viral translation. Conclusion. A study of the role of EMCV-1 L and 2A proteins during the translational processes of an infected cell, first performed using infectious viral pathogens lacking active L and 2A proteins in one experiment, showed that 2A protein is not implicated in the inhibition of cellular translation in HeLa cells; L protein seems to play an important role not only in the specific inhibition of cellular translation but also in maintaining the efficient synthesis of viral proteins; 2A protein is involved not only in primary but also in secondary processing of EMCV-1 capsid proteins.

1 July 2023 in JCO Precision Oncology
Verified
Journal Article
Open access
CNChristopher S. Nabel
Christopher S. Nabel
YHYin P. Hung
Yin P. Hung
AKAnna Kurilovich
Anna Kurilovich
ALAleksandra Lopareva
Aleksandra Lopareva
DDDora Dias-Santagata
Dora Dias-Santagata
ALAbner Louissaint
Abner Louissaint

1 May 2026 in JCO Precision Oncology
Verified
Journal Article
Closed access
DBDhruv Bansal
Dhruv Bansal
BPBen Ponvilawan
Ben Ponvilawan
DGDmitrii Grachev
Dmitrii Grachev
VKVladimir Kushnarev
Vladimir Kushnarev
ATArtem Tarasov
Artem Tarasov
JSJanakiraman Subramanian
Janakiraman Subramanian
PURPOSE: Current predictive biomarkers for immune checkpoint inhibitor (ICI)–based therapy in patients with lung adenocarcinoma (LUAD) or lung squamous cell carcinoma (LUSC), such as PD-L1 protein expression or tumor mutation burden, are still suboptimal. We aim to explore immunophenotypic factors as potential biomarkers in this patient population. METHODS: Clinical, genomic, and transcriptomic data from five patient cohorts, consisting of three publicly available data and two retrospective cohorts, were included. Immune tumor microenvironment (TME) subtype and tertiary lymphoid structure (TLS) signature were evaluated using RNA expression data, and deconvolutional cellular decomposition of tumor samples was performed using the Kassandra algorithm. Survival analysis was performed using a log-rank test and multivariate Cox regression. All statistical analyses were performed using Python version 3.10. RESULTS: In total, 514 patients were included in this analysis. A minority of LUAD (40.8%) had an immune-hot phenotype, which corresponded to better overall survival (OS) and progression-free survival (PFS) than the immune-cold phenotype. TLS-high signature was also associated with a superior ICI response rate and improved PFS, even with multivariate adjustments. Increased T-cell and macrophage infiltration and trafficking were predictive of ICI response. PD-L1 status and KEAP1 or STK11 mutations did not affect the response rates but were associated with poorer OS and PFS. CONCLUSION: Dynamic and active immune recruitment, indicated by immune-hot TME and high TLS score, was predictive of ICI benefit in patients with LUAD. Further prospective studies are warranted to expand to other treatment combinations with PD-(L)1 inhibitors.

3 August 2026
Verified
Other
Open access
PDF file
BUBurak Uzunparmak
Burak Uzunparmak
FSFei Su
Fei Su
AJAmber Johnson
Amber Johnson
KSKenna R. Mills Shaw
Kenna R. Mills Shaw
EKElisabeth K. Kong
Elisabeth K. Kong
FMFunda Meric-Bernstam
Funda Meric-Bernstam
Supplementary Figure S3 shows the association between genomic alteration status and expression of ADC targets.

3 August 2026
Verified
Other
Open access
PDF file
BUBurak Uzunparmak
Burak Uzunparmak
FSFei Su
Fei Su
AJAmber Johnson
Amber Johnson
KSKenna R. Mills Shaw
Kenna R. Mills Shaw
EKElisabeth K. Kong
Elisabeth K. Kong
FMFunda Meric-Bernstam
Funda Meric-Bernstam
Supplementary Table S3 shows treatment status and the expression of ADC targets.

3 August 2026
Verified
Other
Open access
PDF file
BUBurak Uzunparmak
Burak Uzunparmak
FSFei Su
Fei Su
AJAmber Johnson
Amber Johnson
KSKenna R. Mills Shaw
Kenna R. Mills Shaw
EKElisabeth K. Kong
Elisabeth K. Kong
FMFunda Meric-Bernstam
Funda Meric-Bernstam
Supplementary Table S7 shows the summary of therapeutic actions based on CGTP biomarker findings.